Reviva Pharmaceuticals Holdings Inc(RVPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.75 | Insider Own | 1.95% | Shs Outstand | 12.8M | Perf Week | -59.17% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 27.95% | Insider Trans | - | Shs Float | 12.6M | Perf Month | -60.22% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.48 | Inst Own | 17.54% | Short Float | 14.86% | Perf Quarter | -93.13% |
| Income | -0.02B | P/S | - | EPS this Y | 70.62% | Inst Trans | 0.97% | Short Ratio | 2.31 | Perf Half Y | -96.86% |
| Sales | 0.00B | P/B | 0.24 | EPS next 5Y | 43.09% | ROA | -126.42% | Short Interest | 1.87M | Perf YTD | -93.69% |
| Book/sh | 1.47 | P/C | 0.31 | EPS past 3/5Y | 42.61% 26.02% | ROE | -419.97% | 52W High | -98.48% ($23.20) | Perf Year | -97.89% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -229.71% | 52W Low | 34.39% ($0.26) | Perf 3Y | -99.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 62.63% | Gross Margin | - | Volatility(W/M) | 20.23% 11.54% | Perf 5Y | -99.62% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.08 | EPS Q/Q | 80.85% | Profit Margin | - | RSI (14) | 18.88 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | Sales Q/Q | - | SMA20 | -58.19% ($0.84) | Beta | 0.6 | Target Price | $19 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/5/13 | SMA50 | -72.85% ($1.29) | Rel Volume | 0 | Prev Close | $0.35 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -29.58% - | SMA200 | -94.99% ($6.99) | Avg Volume(3M) | 0.81M | Price | $0.35 |
| IPO | 2018/10/18 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
🧠 Reviva Pharmaceuticals Holdings, Inc. (RPHA) is a clinical-stage biotech with a lead asset, brilaroxazine (RP5063), a multi-target molecule that simultaneously modulates serotonin, dopamine, and neuroinflammation signals. The company has generated Phase 3 RECOVER double-blind and 1-year open-label extension (OLE) data in schizophrenia and, following FDA guidance, is preparing a second Phase 3 trial (RECOVER-2). Expansion into additional indications such as bipolar disorder, major depressive disorder (MDD), and ADHD is also planned.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
RVPH has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.6% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.6%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.5%.
Tap to view numbers
It ranks #546 of 598 in the industry
Based on market cap of $5M.
NIKI#544 Niki BioSolutions Inc $5M PER - 
SKYE#545 Skye Bioscience Inc $5M PER - RVPH#546 Reviva Pharmaceuticals Holdings Inc $5M PER - 
AZTR#546 Azitra Inc $4M PER - 
XBIO#547 Xenetic Biosciences Inc $4M PER - 
FAQ
What kind of company is RVPH?
RVPH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RVPH?
The market cap of RVPH is approximately $5M, ranking 5,695 within its sector.
What is the 52-week high and low for RVPH?
RVPH has recorded a 52-week high of $23.20 and a low of $0.26.
